A district court in the Central District decided, Sunday, to consolidate eight class-action suits against producers of the thyroid drug eltroxin.

The suits, claiming damages of more than three billion shekels, were filed last October, after changes in the drug's inactive ingredients were reported to medical personnel but not to patients. The changes caused side effects, some of which required hospitalization.